Dogwood Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Accrued Expenses

Accrued Expenses

12 Months Ended

Dec. 31, 2022

Accrued Expenses

Accrued Expenses

5. Accrued Expenses

Accrued expenses consist of the following:


		December 31,			December 31,
		2022			2021
Accrued compensation		$	159,704		$	532,678
Accrued interest on preferred members’ interests			188,085			188,085
Accrued clinical research costs			78,349			138,522
Accrued director fees			31,000			31,000
Accrued professional fees			11,600			24,100
Other miscellaneous accrued expenses			1,360			7,375
		$	470,098		$	921,760